SynthesisFrontiers in immunology2026
Biomarkers for differentiating diabetic periodontitis from chronic periodontitis: a systematic review and meta-analysis.
Synthesis in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Diabetes-related periodontitis (DMCP) and chronic periodontitis (CP) are associated with significant differences in clinical presentation, pathogenesis, and treatment outcomes. However, reliable biomarkers for their early differentiation remain elusive. This study aims to identify discriminatory biomarkers between DMCP and CP to provide an evidence-based foundation for improved clinical management. Methods: A systematic search of PubMed, Embase, the Cochrane Library, and Web of Science was conducted from their inception until October 2025 for studies comparing biomarkers in DMCP and CP. Differences in biomarker levels between the two groups were expressed as Standardized Mean Differences (SMD) with 95% Confidence Intervals (CI). All meta-analyses were performed using a random-effects model. Results: A total of 33 eligible studies were included, involving 970 patients with DMCP and 905 with CP. The meta-analysis revealed the following: (1) lipid profiles: the DMCP group demonstrated significantly higher levels of very low-density lipoprotein (VLDL) (SMD: 0.91; 95%CI: 0.43 to 1.39; Conclusions: Significant differences in biomarkers related to lipid metabolism, inflammatory response, and oxidative stress were observed between patients with DMCP and CP. Key indicators demonstrating relatively robust differences include VLDL, 4-HNE, CAT, GSSG, NOS, IL-8, hs-CRP, and C-peptide. Systematic Review Registration: https://inplasy.com/inplasy-2025-11-0067/, identifier INPLASY2025110067.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.